[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Lin et al., 2020 - Google Patents

Pharmacokinetics of N‐ethylpentylone and its effect on increasing levels of dopamine and serotonin in the nucleus accumbens of conscious rats

Lin et al., 2020

View PDF
Document ID
9454366739619002566
Author
Lin Z
Chen Y
Li J
Xu Z
Wang H
Lin J
Ye X
Zhao Z
Shen Y
Zhang Y
Zheng S
Rao Y
Publication year
Publication venue
Addiction Biology

External Links

Snippet

N‐Ethylpentylone (NEP) is one of the most confiscated synthetic cathinones in the world. However, its pharmacology and pharmacokinetics remain largely unknown. In this study, the pharmacokentics of NEP in rat nucleus accumbens (NAc) was assessed via brain …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Similar Documents

Publication Publication Date Title
Lin et al. Pharmacokinetics of N‐ethylpentylone and its effect on increasing levels of dopamine and serotonin in the nucleus accumbens of conscious rats
den Hollander et al. Long-term cognitive and neurochemical effects of “bath salt” designer drugs methylone and mephedrone
Garrod et al. High‐resolution 1H NMR and magic angle spinning NMR spectroscopic investigation of the biochemical effects of 2‐bromoethanamine in intact renal and hepatic tissue
Zollinger et al. Absorption, distribution, metabolism, and excretion (ADME) of 14 C-sonidegib (LDE225) in healthy volunteers
Calinski et al. A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
Chaudhari et al. Determination of metformin bio-distribution by LC-MS/MS in mice treated with a clinically relevant paradigm
de Castro-Neto et al. Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion
Braman et al. A randomized phase I evaluation of CTP‐499, a novel deuterium‐containing drug candidate for diabetic nephropathy
CA2858368A1 (en) Methods for determining total body skeletal muscle mass
Wang et al. Class I HDAC imaging using [3H] CI-994 autoradiography
Bartlett et al. Paraquat is excluded by the blood brain barrier in rhesus macaque: An in vivo pet study
Melega et al. l-Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of In Vivo Deprenyl-Derivedl-Methamphetamine
Nara et al. A fatal case of poisoning with fentanyl transdermal patches in Japan
Kashihara et al. Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation
Moreno et al. Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability 1
PT96829A (en) METHOD FOR TESTING AMINOGUANIDINE AND ITS ANALOGS
Cai et al. Comprehensive isotopomer analysis of glutamate and aspartate in small tissue samples
Krösser et al. Investigation of sarizotan’s impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial
Ellefsen et al. Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry
Rao et al. Precolumn derivatization followed by liquid chromatographic separation and determination of tramiprosate in rat plasma by fluorescence detector: Application to pharmacokinetics
King et al. Determination of the route of excretion of robenacoxib (Onsior™) in cats and dogs: A pilot study
Thiollier et al. Permeability of blood–brain barrier in macaque model of 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐induced Parkinson disease
Chao et al. Quantitative analysis of binding sites for 9‐fluoropropyl‐(+)‐dihydrotetrabenazine ([18F] AV‐133) in a MPTP‐lesioned PD mouse model
Ahmed et al. Interference with AGEs formation and AGEs-induced vascular injury mediates curcumin vascular protection in metabolic syndrome
Rouxinol et al. Pharmacokinetics, pharmacodynamics, and toxicity of the new psychoactive substance 3, 4-dimethylmethcathinone (3, 4-DMMC)